If you or someone you know is facing advanced cervical cancer, understanding how treatment might work is crucial. A recent study looked at how certain imaging results could predict outcomes for patients receiving PD-1 inhibitors, a type of immunotherapy. The findings showed that lower values of substantial tumor ADC, which measures how water moves in tumor tissue, were linked to significantly worse progression-free survival and overall survival. In simpler terms, if the ADC values are low, patients might not respond as well to the treatment. This information could help doctors make better decisions about treatment plans, potentially steering patients toward options that could work better for them. Knowing this could empower patients and their families to have informed discussions with their healthcare teams about the best path forward.
Low sADC Predicts Poor Outcomes in Cervical Cancer with PD-1 InhibitorsCan imaging predict how well cervical cancer patients respond to treatment?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Use sADC to predict outcomes in cervical cancer patients on PD-1 inhibitors.
This retrospective study evaluated whether pre-treatment apparent diffusion coefficient (ADC) values from diffusion-weighted imaging could predict clinical outcomes in patients with advanced or locally advanced cervical cancer undergoing PD-1 inhibitor therapy. Conducted at Wuhan Union Hospital, the study included 167 patients treated between May 1, 2020, and December 31, 2023. Researchers measured whole tumor ADC (wADC) and substantial tumor ADC (sADC), which excludes necrotic, cystic, and vascular regions, on the largest tumor slice. Optimal cut-off values for ADC and inflammatory markers were determined using X-tile software based on overall survival (OS). The analysis revealed that a lower sADC was significantly associated with worse progression-free survival (PFS) and overall survival (OS), with hazard ratios of 1.81 (95% CI: 1.18-2.80, P=0.005) and 2.40 (95% CI: 1.36-4.21, P=0.002), respectively. In contrast, wADC did not show a significant prognostic correlation with PFS (HR=0.64, 95% CI: 0.39-1.06, P=0.123) or OS (HR=0.62, 95% CI: 0.32-1.19, P=0.209). Multivariate Cox regression confirmed low-sADC as an independent risk factor for both OS (HR=2.15, 95% CI: 1.14-4.03, P=0.017) and PFS (HR=1.70, 95% CI: 1.08-2.67, P=0.021). These findings suggest that sADC could serve as a prognostic biomarker in this patient population.
What this means for you:
Lower tumor ADC values may indicate poorer treatment outcomes for cervical cancer patients on PD-1 inhibitors. More on Cancer
PD-1/PD-L1 inhibitors improve response in dMMR/MSI-H metastatic colorectal cancer
New meta-analysis shows PD-1 inhibitors improve response rates for dMMR colorectal cancer
This meta-analysis of 1460 patients with dMMR/MSI-H metastatic colorectal cancer found that PD-1/PD-L1 monotherapy significantly improved ob…
A large review of 1460 patients found PD-1 inhibitors significantly improved tumor response rates compared to chemotherapy for dMMR colorect…
Sequential SBRT, pembrolizumab, and resection in oligometastatic colorectal cancer shows 60% 1-year RFS
Phase Ib trial shows promising signs for colorectal cancer treatment
This Phase Ib clinical trial evaluated sequential stereotactic body radiotherapy, pembrolizumab, and resection in 15 patients with oligometa…
A Phase Ib trial found that a specific combination therapy helped 60% of patients stay free from cancer recurrence for one year.
Phase 2 trial of pembrolizumab and DNA vaccines in metastatic prostate cancer shows no significant difference
Prostate Cancer Vaccine Strategy Shows Tumor Responses, But One Arm Adds Risk
This early Phase 2 trial evaluated pembrolizumab combined with pTVG-HP or pTVG-AR DNA vaccines in 60 patients with metastatic castration-res…
A two-vaccine strategy did not improve survival over a single vaccine in advanced prostate cancer, yet both approaches shrank tumors in some…
Pembrolizumab Plus Paclitaxel Improves Survival in Recurrent Ovarian Carcinoma Compared to Paclitaxel Alone
New Drug Combo Extends Survival for Tough Ovarian Cancer
This randomised, double-blind phase 3 study evaluated pembrolizumab plus paclitaxel versus placebo plus paclitaxel in 643 female participant…
This new combination offers a meaningful survival boost for women with recurrent ovarian cancer that has become resistant to standard treatm…
View Original Abstract ↓
BackgroundTo investigate whether pre-treatment apparent diffusion coefficient (ADC) values from diffusion-weighted imaging (DWI) predict clinical outcomes in patients with advanced or locally advanced cervical cancer undergoing Programmed Death-1 (PD-1) inhibitor therapy. Despite the growing use of immunotherapy, reliable and non-invasive imaging biomarkers to predict treatment response in cervical cancer are lacking.MethodsThis retrospective study analyzed 167 cervical cancer patients treated with PD-1 inhibitors at Wuhan Union Hospital between 01/05/2020 and 31/12/2023. The whole tumor ADC (wADC) and substantial tumor ADC (sADC; excluding necrotic, cystic, and vascular regions) were measured on the largest tumor slice. Optimal cut-off values for ADC and inflammatory markers were determined using X-tile software based on overall survival (OS). Progression-free survival (PFS) and OS were analyzed using Kaplan-Meier curves and Cox regression models.ResultsLower sADC was associated with significantly worse PFS (hazard ratio [HR] = 1.81; 95% confidence interval [CI]: 1.18-2.80; P = 0.005) and OS (HR = 2.40; 95% CI: 1.36-4.21; P = 0.002), whereas wADC showed no significant prognostic correlation with PFS (HR = 0.64; 95% CI: 0.39-1.06; P = 0.123) and OS (HR = 0.62; 95% CI: 0.32-1.19; P = 0.209). Multivariate Cox regression revealed low-sADC as an independent risk factor for OS (HR = 2.15, 95% CI: 1.14-4.03, P = 0.017) and PFS (HR = 1.70, 95% CI: 1.08-2.67, P = 0.021).ConclusionThe substantial tumor ADC (excluding necrotic, cystic, and vascular regions) was associated with prognosis in cervical cancer patients receiving PD-1 inhibitor therapy.
Experimental agents show response rates up to 70% in relapsed or refractory diffuse large B-cell lymphoma
New cancer therapies double response rates for tough lymphoma
Related in Oncology
Sacubitril/Valsartan preserves left ventricular systolic function and attenuates GLS deterioration during chemotherapy
Sacubitril and Valsartan May Protect Heart Function During Chemotherapy
This meta-analysis of randomized controlled trials evaluates sacubitril/valsartan for patients undergoing chemotherapy to manage chemotherap…
A new review suggests the medication sacubitril/valsartan may help preserve heart muscle function for patients undergoing chemotherapy.
DaVinci Single-Port transoral robotic surgery is feasible across multiple indications including oncology and sleep apnea
Single-Port Robot Shows Promise for Sleep Apnea Surgery
This systematic review and meta-analysis of 479 patients evaluates the feasibility of DaVinci Single-Port (SP) transoral robotic surgery (TO…
A new analysis finds single-port robotic surgery for sleep apnea is feasible, with short operating times and low blood loss.
Neoadjuvant chemoimmunotherapy achieves higher pathological complete response rates than chemotherapy alone in muscle-invasive bladder cancer
Chemoimmunotherapy Shows Higher Response Rates in Bladder Cancer
This network meta-analysis of 2234 patients with muscle-invasive bladder cancer compares neoadjuvant chemoimmunotherapy (NICT), chemotherapy…
A new analysis shows that combining chemotherapy and immunotherapy may lead to higher response rates for patients with muscle-invasive bladd…
MRI Radiomics Predicts TERTp Mutation in Glioma with Moderate Accuracy
MRI Radiomics Help Predict TERTp Mutation in Glioma Patients
Meta-analysis of 14 studies shows MRI radiomics predicts TERTp mutation in glioma with AUC 0.79; combined models improve accuracy to 0.82.
New analysis shows MRI-based radiomics can help predict specific genetic mutations in glioma, potentially aiding early diagnosis and treatme…
From Other Specialties
Post-extubation dysphagia incidence ranges from 28.36% to 68.94% in critically ill children
High rates of swallowing problems found in children after intubation
This scoping review of 15 studies examines the incidence and predictors of pediatric post-extubation dysphagia (PED). The authors identify h…
Many critically ill children struggle to swallow safely after breathing tubes are removed, with some studies showing issues in up to 69% of …
Circular RNAs may regulate ferroptosis and anti-tumor immunity in cancer via multiple mechanisms
Circular RNAs may offer new ways to target cancer cells
This systematic review explores how circular RNAs (circRNAs) act as molecular bridges to simultaneously regulate ferroptosis and anti-tumor …
New research identifies circular RNAs as molecular bridges that could help doctors diagnose and treat cancer more precisely.
Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy
New approach targets the immune system to treat brain tumors
This systematic review explores how targeting the meningeal immune system, including dural lymphatics and rBAMs, could overcome current barr…
A new strategy focuses on the area where brain tumors meet the body's defenses to improve how immunotherapy works for glioblastoma.
A 6 dimension and 42 item system provides early risk assessment for high-risk diabetic feet
Experts Develop New Risk Assessment System for Diabetic Feet
This expert consultation and guideline describes the development of an early risk assessment system for high-risk diabetic feet. The consens…
A new assessment system identifies risk factors like nerve damage and circulation to help manage and prevent complications in patients with …